Zur Kurzanzeige

Führen Leitlinienempfehlungen zur Polypharmazie bei Patienten mit Typ 1- und Typ 2- Diabetes?

dc.contributor.advisorNauck, Michael A. Prof. Dr.
dc.contributor.authorBauer, Svenja
dc.date.accessioned2015-02-03T13:04:45Z
dc.date.available2015-02-23T23:50:05Z
dc.date.issued2015-02-03
dc.identifier.urihttp://hdl.handle.net/11858/00-1735-0000-0022-5DA3-7
dc.identifier.urihttp://dx.doi.org/10.53846/goediss-4897
dc.language.isodeude
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subject.ddc610de
dc.titleFühren Leitlinienempfehlungen zur Polypharmazie bei Patienten mit Typ 1- und Typ 2- Diabetes?de
dc.typedoctoralThesisde
dc.title.translatedPolypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelinesde
dc.contributor.refereeNauck, Michael A. Prof. Dr.
dc.date.examination2015-02-16
dc.description.abstractengAIMS: Our aim was to assess the number of medications prescribed to people with Type 1 or Type 2 diabetes mellitus and to compare these to recommendations by guidelines. PATIENTS AND METHODS: Data from 155 and 154 people with Type 1 and Type 2 diabetes, respectively, were analysed. Prescribed medications (glucose-lowering drugs, blood pressure medications, drugs to treat cardiovascular risk or diseases, etc.) were counted as compounds per day, tablets per day, injections per day, or other modes of administration. RESULTS: People with Type 2 diabetes were prescribed 8.4 ± 3.0 different drug compounds per day (maximum, 16), 8.6 ± 3.9 tablets per day (maximum, 22), 2.6 ± 1.6 injections per day (maximum, 7), in total 11.6 ± 4.5 doses of any medication per day (maximum, 27). The numbers for people with Type 1 diabetes were 5.5 ± 3.4 compounds per day (maximum, 15), 4.5 ± 4.3 tablets per day (maximum, 18), 3.9 ± 2.2 injections per day (maximum, 8), in total 8.5 ± 5.1 doses of any medication per day (maximum, 22). Over 97% of the prescriptions corresponded to recommendations by guidelines. CONCLUSIONS: The number of prescribed drugs is high in people with diabetes mellitus, and higher for those with Type 2 than with Type 1 diabetes. The compatibility of prescriptions with guideline recommendations suggests that even this high number of prescriptions will provide a clinical benefit. The current analysis could provide a basis for a realistic judgement of the burden imposed by polypharmacy in people with diabetes mellitus.de
dc.contributor.coRefereeHimmel, Wolfgang Prof. Dr.
dc.contributor.thirdRefereeRaddatz, Dirk Prof. Dr.
dc.subject.gerDiabetes mellitusde
dc.subject.gerPolypharmaziede
dc.subject.gerLeitliniende
dc.subject.engPolypharmacyde
dc.subject.engGuidelinesde
dc.subject.engDiabetes mellitusde
dc.identifier.urnurn:nbn:de:gbv:7-11858/00-1735-0000-0022-5DA3-7-2
dc.affiliation.instituteMedizinische Fakultätde
dc.subject.gokfullMedizin (PPN619874732)de
dc.description.embargoed2015-02-23
dc.identifier.ppn81728723X


Dateien

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige